A5004596365- Health Systems, Economic Evaluations, Quality of Life
- Rheumatoid Arthritis Research and Therapies
- Cancer Immunotherapy and Biomarkers
- Multiple Myeloma Research and Treatments
- Lung Cancer Treatments and Mutations
- Biosimilars and Bioanalytical Methods
- Pneumonia and Respiratory Infections
- Economic and Financial Impacts of Cancer
- Lymphoma Diagnosis and Treatment
- Opioid Use Disorder Treatment
- Musculoskeletal pain and rehabilitation
- Renal cell carcinoma treatment
- Schizophrenia research and treatment
- CAR-T cell therapy research
- Chronic Lymphocytic Leukemia Research
- Sexuality, Behavior, and Technology
- Pharmaceutical Economics and Policy
- Cancer Treatment and Pharmacology
- Treatment of Major Depression
- Sexual function and dysfunction studies
- Bipolar Disorder and Treatment
- Microscopic Colitis
- Healthcare Policy and Management
- Protein Degradation and Inhibitors
- Respiratory and Cough-Related Research
Regeneron (United States)
2021-2025
Pfizer (United States)
2011-2020
Ibero American University
2016-2019
Children's Cancer Center
2018
Baylor College of Medicine
2018
University of Pennsylvania
2018
Dana-Farber Cancer Institute
2018
Memorial Sloan Kettering Cancer Center
2005
Presbyterian Hospital
2005
OBJECTIVE Several second-generation antipsychotic (SGA) drugs have been associated with weight gain, hyperglycemia, and dyslipidemia. We evaluated whether glucose lipid testing increased after the American Diabetes Association (ADA) consensus statement recommending metabolic monitoring for SGA-treated patients. RESEARCH DESIGN AND METHODS Laboratory claims serum were identified an incident cohort of 18,876 adults initiating SGA in a U.S. commercial health plan (2001–2006) control group...
The widespread adoption of electronic health records (EHRs) and the growing wealth digitized information sources about patients is ushering in an era 'Big Data' that may revolutionize clinical research oncology. Research will likely be more efficient potentially accurate than current gold standard manual chart review studies. However, EHRs as they exist today have significant limitations: important data elements are missing or only captured free text PDF documents. Using two case studies, we...
A national cardiometabolic screening program for patients in a variety of public mental health facilities, group practices, and community behavioral clinics was funded by Pfizer Inc. between 2005 2008.A one-day, voluntary metabolic fair the United States offered attending free same-day feedback to physicians from biometrics testing third party that compliant with Health Insurance Portability Accountability Act.This analysis included 10,084 at 219 sites; 2,739 (27%) reported having fasted...
The risk of community-acquired pneumonia (CAP) increases with age and significantly impacts morbidity mortality in the elderly population. burden illness cost preventing CAP has not been compared to other serious diseases. This retrospective analysis used claims data from 2014 2015 hospitalizations for CAP, myocardial infarction (MI), stroke, osteoporotic fractures (OF) adults aged ≥65 years enrolled a Medicare Advantage insurance plan. Individuals who had already hospitalized one these...
This study provides national data on community mental health centers' (CMHCs') capacity to screen for and address their clients' general medical conditions.A survey was distributed members of the National Council Community Behavioral Healthcare, oldest largest association CMHCs.Among 181 CMHCs responding survey, more than two-thirds reported having protocols or procedures common problems (hypertension, obesity, dyslipidemia, diabetes). However, only one-half could provide treatment referral...
Aims To quantify patient preferences for attributes of novel treatments triple-class–exposed (TCE) relapsed and/or refractory multiple myeloma (RRMM).
Objectives: To calculate the fibromyalgia (FM) burden of illness (BOI) from employer perspective and to compare annual prevalence, work output, absence, health benefit costs employees with FM versus osteoarthritis (OA). Methods: Retrospective regression model analysis comparing objective total (health care, prescription drug, sick leave, disability, workers' compensation) costs, absence days for FM, OA NoFM cohorts, while controlling differences in patient characteristics. Results:...
Real-world data comparing tofacitinib with biologic disease-modifying antirheumatic drugs (bDMARDs) are limited.To compare characteristics, treatment patterns, and costs of patients rheumatoid arthritis (RA) receiving versus the most common bDMARDs (adalimumab [ADA], etanercept [ETN], abatacept [ABA]) following a single bDMARD in U.S. administrative claims database.This study was retrospective cohort analysis aged ≥ 18 years an RA diagnosis (ICD-9-CM codes 714.0x-714.4x; 714.81) 1 previous...
To examine treatment patterns, dosing, health care resource utilization, and cost of tumor necrosis factor inhibitors (TNFi), adalimumab (ADA) infliximab (IFX), among patients enrolled in US Humana insurance plans who have been diagnosed with ulcerative colitis (UC).This retrospective cohort study identified the first pharmacy or medical claim for ADA IFX (from January 1, 2007, to December 31, 2014) continuous enrollment 6 months more preindex 12 postindex, one UC diagnosis pre- postindex....
To evaluate 12-month treatment patterns, healthcare resource use (HCRU), and costs for patients with rheumatoid arthritis (RA), following initiation of index TNF inhibitors (TNFi) subsequent biologic DMARDs (bDMARDs).This was a retrospective cohort analysis adults RA newly initiating TNFi in the Truven Marketscan Commercial Claims Encounters Medicare Supplemental Databases during 2010-2013. A sub-group who switched to bDMARD within 12 months post-index 180 days last were subsequently...
Evidence of humanistic detriments Clostridium difficile infection (CDI) remains limited. To assess burden associated with CDI. Self-reported National Health and Wellness Survey data between 2013 2016 were analyzed for the USA, five European countries, China, Brazil. Outcome measures included SF-36v2® health-related quality life (HRQoL) Work Productivity Activity Impairment questionnaire. Respondents (≥ 18 years old) classified as (1) currently treated doctor-diagnosed CDI (C-CDI), (2) prior...
BACKGROUND: Adherence to biologic disease-modifying antirheumatic drugs (bDMARDs) among patients with rheumatoid arthritis (RA) is often suboptimal in routine clinical practice. Low or nonadherence can reduce the effectiveness of bDMARD therapies. OBJECTIVE: To evaluate filling newly prescribed initial bDMARDs for treatment RA and potential characterizing decisions patient outcomes. METHODS: In this retrospective cohort analysis, aged ≥ 18 years an diagnosis (ICD-9-CM code 714.xx) were...
Objective: The study aims to determine from the physician's perspective, conditions and symptoms most relevant diagnosis of fibromyalgia (FM) for identifying International Classification Diseases-diagnosis codes prescription medications evaluate FM-related healthcare resource utilization. Methods: A questionnaire was administered using an online physician network (SERMO™) which responses 102 physicians were evaluated: anesthesiologists (n = 6), neurologists 18), primary care 16), pain...
To evaluate the prevalence, characteristics, associated healthcare resource utilization (HRU), and costs of diagnosed prescription opioid abusers (abusers) in a managed care population.Patients aged ≥12 years with claim for abuse were identified Thomson MarketScan Commercial Medicare Supplemental research databases between January 1, 2005 September 30, 2010. HRU (per patient per month) calculated all patients an index date (date diagnosis) from October 2008 to 2009 continuous eligibility...
Sunitinib and pazopanib are among the most prescribed targeted therapies for systemic management of advanced renal cell carcinoma (RCC), but published cost comparisons between 2 agents few limited by methodological population differences. Also, sunitinib is administered on a 4-week on/2-week off cycle, taken continuously. Thus, appropriate use drugs require approaches to account these One way accomplish this substitute expected observed days supply. Recognizing effects nonrepresentative...
Erectile dysfunction (ED) can lead to treatment noncompliance in patients taking medications for chronic health conditions. Using the Intelligent Health Repository, NDCHealth's longitudinal, United States care claims database, we examined impact of treating ED on adherence long-term therapies previously nonadherent patients. Male ≥18 years age were identified who received antidepressant (AD), antihypertensive (AH), oral hypoglycemic (OHG), or lipid-lowering (LL) agents and initiated therapy...
Abstract Background In the EMPOWER‐Lung 1 trial ( ClinicalTrials.gov , NCT03088540), cemiplimab conferred longer survival than platinum‐doublet chemotherapy for advanced non–small cell lung cancer (NSCLC) with programmed death‐ligand (PD‐L1) ≥50%. Patient‐reported outcomes were evaluated among participants. Methods Adults NSCLC and Eastern Cooperative Oncology Group performance status 0 to randomly assigned 350 mg every 3 weeks or chemotherapy. At baseline day of each treatment cycle,...